Advertisement

Topics

ICAgen Company Profile

06:28 EDT 21st September 2017 | BioPortfolio

Icagen is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. Ion channels are protein structures found in virtually every cell of the human body. Ion channels span the cell membrane and regulate the flow of ions, which are charged particles such as sodium, potassium, calcium and chloride, into and out of cells. There are currently 35 drugs that modulate ion channels and are marketed by third parties for multiple therapeutic indications. Key elements of our ion channel technology include our cloning of over 300 human ion channel genes, which we believe represents substantially all of the human ion channel genome; expertise in developing high throughput screens for ion channel targets; ion channel focused chemistry libraries of over 200,000 compounds; proprietary computational chemistry methods; an extensive ion channel database, which integrates biological and chemical information about our targets and compounds; pharmacology and bioanalytic capabilities; and an extensive intellectual property portfolio. By integrating a number of scientific and drug development disciplines, we are able to efficiently discover and develop small molecule compounds that are more specific for the medically relevant ion channel, and therefore have a reduced likelihood of adverse side effects and clinical failure. We pursue a target class approach to ion channel drug discovery. In this approach, we start with all potential ion channel targets and seek to identify applications to the treatment of various diseases. We believe that our approach provides for a more efficient drug discovery process, because our in-depth understanding of the targets and methods for finding small molecule modulators of these targets, obviates the need to develop new research tools each time a new target is identified. Instead, we use our knowledge and skill to quickly find potential small molecule modulators of particular ion channel targets. We then use these small molecules to validate the particular target in a relevant animal model of disease. If a small molecule demonstrates activity in the animal model, it both validates the target and provides a starting point for further medicinal chemistry efforts. Utilizing our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates that modulate ion channels. Our four most advanced programs are: sickle cell disease, for which the company is evaluating future development options; lead compounds for epilepsy and neuropathic pain, for which the Company is conducting preclinical studies; a compound for atrial fibrillation, for which the Company’s collaborator Bristol-Myers Squibb Company is conducting preclinical studies; and lead compounds for dementia, including Alzheimer’s disease, for which the Company’s collaborator Astellas Pharma Inc. is conducting preclinical studies, and lead compounds for attention deficit/hyperactivity disorder, which were derived from the collaboration and for which the Company is conducting preclinical studies. We are also conducting ongoing drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders and glaucoma. In addition to our internal programs, we have established collaborations with McNeil Pediatrics, Bristol-Myers Squibb and Yamanouchi to further capitalize on our ion channel capabilities.

Location

4222 Emperor Blvd., Suite 350
Durham
NC
27703
United States of America

Contact

Phone: (919) 941-5206
Fax: (919) 941-0813
Email: InvestorsandPress@icagen.com


News Articles [7 Associated News Articles listed on BioPortfolio]

Icagen. Omdana Therapeutics partner to advance discovery of novel medicines for pulmonary hypertension

Icagen and Omdana Therapeutics, have announced a collaboration to help advance the discovery of novel medicines for disorders related to tissue homeostasis and vascular remodeling such as pulmonary hy...

Icagen, Inc. And Announce Collaboration To Pursue Therapies For Patients With Pulmonary Hypertension

  Life Sciences Jobs   ...

Icagen Inc Strategic SWOT Analysis Review [Report Updated: 27072017] Prices from USD $125

Icagen Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analy...

Icagen Inc Strategic SWOT Analysis Review [Report Updated: 18072017] Prices from USD $125

Icagen Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analy...

Icagen to Showcase its Integrated Drug Discovery Platform at BIO International

DURHAM, N.C., May 24, 2017 /PRNewswire/ -- Icagen, Inc., an early drug discovery partner, today announced it will be showcasing its integrated drug discovery capabilities at BIO International, being h...

Icagen and Omdana Therapeutics Announce Collaboration to Pursue Therapies for Patients with Pulmonary Hypertension

DURHAM, N.C., June 20, 2017 /PRNewswire/ -- Today Icagen, Inc. and Omdana Therapeutics, Inc. announced a collaboration to help advance the discovery of novel medicines for disorders related to ti...

Icagen Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 26072017] Prices from USD $250

SummaryIcagen Inc Icagen formerly known as XRpro Sciences, Inc. is a biopharmaceutical company which develops drug candidates to unmet medical need and commercial opportunity. The company discovers dr...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Icagen, Inc.

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule...

ICAgen

Icagen is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that modulate ion channel targets. The company has developed an integrat...

More Information about "ICAgen" on BioPortfolio

We have published hundreds of ICAgen news stories on BioPortfolio along with dozens of ICAgen Clinical Trials and PubMed Articles about ICAgen for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ICAgen Companies in our database. You can also find out about relevant ICAgen Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record